Elecsys® Alzheimer’s Disease Testing Sites
Biomarkers to support early diagnosis of Alzheimer’s Disease
Australian laboratories offering Elecsys® Alzheimer’s Disease testing:
Please note this is a list of laboratories made availalbe for Health Care Professionals (HCP) to contact the laboratory. Patients should speak to their HCP as test results must be used in conjunction with other clinical information.
Victoria
A/Prof Qiao-Xin Li, PhD
Principal Research Fellow
Email: [email protected]
Blood tests: pTau 217, pTau 181, NfL
CSF tests: Abeta 1-42, pTau 181, total Tau, NfL
Research tests: GFAP, NfL, Abeta 40 CSF
Victoria
St. Vincent's Hospital Melbourne
Dr Christina Trambas
Medical Director | Chemical Pathologist
Email: [email protected]
Ph: +61 3 9231 3339
Blood tests:
CSF Tests: Abeta 1-42 CSF, pTau 181, total Tau.
ApoE genotyping
New South Wales
Dr Phoebe Stanford
Staff Specialist, Chemical Pathology
Email: [email protected]
Ph: +61 2 9767 6663
Blood tests:
CSF Tests: Abeta 1-42,p Tau 181,total tau
South Australia
Dr Mohamed Saleem
Consultant Chemical Pathologist | SA Pathology
Email: [email protected]
Ph: +61 8 8222 3561
Blood tests:
CSF Tests: Abeta 1-42,p Tau 181,total tau
Queensland
Dr Gemma Daley
Chemical Pathologist
Email: [email protected]
Blood tests: pTau 217, pTau 181
NB: samples collected via Sonic collection rooms nationally
Queensland
Blood tests: pTau 217, pTau 181,
NB: sample collection and transport for testing by NDDL at
the Florey is facilitated by Healius collections rooms nationally
The path to an Alzheimer’s diagnosis is a maze of uncertainty. What if a simple blood test could bring a clearer, more confident path toward diagnosis, especially for those in earlier stages of cognitive decline? The Elecsys® pTau 217 assay redefines the current diagnosis pathway by providing a minimally invasive, blood based solution. It informs clinical assessments and decisions and provides reliable insights for conversations with patients. Helping families plan for the future with clarity.
The Elecsys® pTau217 blood test is Australia's first clinically validated blood test included on the ARTG to both rule in and rule out amyloid pathology across and primary care and specialist settings. The test measures phosphorylated Tau 217 (pTau 217), an indicator of amyloid pathology and a hallmark of Alzheimer's disease and is intended to be used for individuals aged 55 years and older with signs, symptoms or complaints of cognitive decline.1
Reference: 1: Elecsys Phospho-Tau (217P) Plasma method sheet 10285583500V1.0